DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Pharmacokinetics, Safety, and Tolerability of Subcutaneous GAMUNEX-C in Pediatric Subjects With Primary Immunodeficiency

Information source: Grifols Therapeutics Inc.
Information obtained from ClinicalTrials.gov on February 07, 2013
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Primary Immunodeficiency

Intervention: GAMUNEX®-C (Biological); GAMUNEX®-C (Biological)

Phase: Phase 4

Status: Recruiting

Sponsored by: Grifols Therapeutics Inc.

Overall contact:
Rhonda Griffin, Email: Rhonda.Griffin@Grifols.com

Summary

The purpose of this open-label study is to evaluate the pharmacokinetics, safety, and tolerability of subcutaneously (SC; under the skin) administered GAMUNEX-C compared to intravenously (IV; through the vein) administered GAMUNEX-C in subjects 2-16 years of age with Primary Immunodeficiency.

Clinical Details

Official title: An Open-label, Single-sequence, Crossover Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Subcutaneous GAMUNEX-C in Pediatric Subjects With Primary Immunodeficiency

Study design: Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Pharmacokinetics of SC GAMUNEX-C compared to IV GAMUNEX-C in pediatric (2-16 years old) patients with Primary Immunodeficiency

Secondary outcome: Safety (including incidence of adverse events and site infusion reactions) of SC GAMUNEX-C in pediatric (2-16 years old) patients with Primary Immunodeficiency

Eligibility

Minimum age: 2 Years. Maximum age: 16 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Aged 2-16 years old, inclusive.

- Documented and confirmed pre-existing diagnosis of PI with features of

hypogammaglobulinemia requiring immunoglobulin replacement.

- Currently on IgG replacement therapy with a serum IgG trough concentration of ≥ 500

mg/dL at the Screening Visit.

- Adequate normal skin to allow for SC infusions.

- Signs an assent form, if applicable (per Institutional Review Board [IRB]

requirements). Parent or legal guardian must sign an informed consent form.

- Females of childbearing potential must have a negative urine pregnancy test result

and must practice an effective form of contraception (which may include abstinence).

Exclusion Criteria:

- History of anaphylaxis or severe systemic response to an immunoglobulin or blood

product.

- History of blistering skin disease, clinically significant thrombocytopenia, bleeding

disorder, recurrent skin infections or other disorders where subcutaneous therapy could be contraindicated.

- Has a specific antibody deficiency disorder, IgG subclass deficiency, or transient

hypogammaglobulinemia of infancy.

- History of severe adverse reaction to parenteral products containing immunoglobulin A

(IgA).

- Significant proteinuria and/or has a history of acute renal failure and/or severe

renal impairment (serum creatinine more than 2. 5 times the upper limit of normal [ULN] for age and gender) and/or is on dialysis.

- Known substance or prescription drug abuse in the past 12 months.

- Acquired medical condition that is known to cause secondary immune deficiency.

- Receiving any of the following medications: systemic corticosteroids (long term

daily, >1 mg of prednisone equivalent/kg/day for >30 days) (intermittent courses would not exclude subject); immunosuppressants (i. e., antimetabolites and systemic calcineurin inhibitors; NOTE: inhaled steroids are allowed); or immunomodulators.

- Non-controlled arterial hypertension at a level of ≥ the 90th percentile blood

pressure (either systolic or diastolic) for age and height (based on http://www. nhlbi. nih. gov/guidelines/hypertension/child_tbl. pdf ).

- History or current diagnosis of thrombotic episodes; venous thrombus that occurred in

association with a medical device > 2 years prior to screening are allowed.

- Currently receiving anti-coagulation therapy.

- History of Kawasaki disease.

- Participated in another clinical trial involving exposure to an investigational

product or device within 30 days prior to screening (imaging studies without investigative treatments are permitted) or has received any investigational blood product within the previous 3 months.

- Unable or unwilling to comply with any aspect of the protocol, including blood

sampling and completion of the Infusion Site Reactions pages in the SC Infusion Diary.

- In the opinion of the Investigator the subject may have compliance problems with the

protocol and the procedures of the protocol.

- Pregnant or lactating.

- Clinical evidence of any significant acute or chronic disease that, in the opinion of

the Investigator, may interfere with successful completion of the study.

Locations and Contacts

Rhonda Griffin, Email: Rhonda.Griffin@Grifols.com

Childrens Hospital Los Angeles, Los Angeles, California 90027, United States; Recruiting

IMMUNOe International Research Centers, Centennial, Colorado 80112, United States; Recruiting

Joe DiMaggio Children's Hospital, Hollywood, Florida 33021, United States; Recruiting

University of Iowa Hospitals and Clinic, Iowa City, Iowa 52242, United States; Recruiting

The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania 19104, United States; Recruiting

Additional Information

Starting date: November 2011
Last updated: January 17, 2013

Page last updated: February 07, 2013

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012